Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Jeffrey Walch
Bernstein Institutional Services LLC, Research Division

Hi. My name is Jeffrey Walch. I co-lead the U.S. biotechnology coverage at Bernstein. Very excited today to have a nice fireside chat with Michael Morrissey, PhD, President and Chief Executive Officer of Exelixis. Look forward to the conversation and thank you for attending.

Michael Morrissey
CEO, President & Director

All right. Great to be here. Thanks for the invitation today and looking forward to — we had a great day. Looking forward to a great conversation. Before I begin, let me just state that I’ll be making forward-looking statements today. So people listening should see our SEC filings for a description of the risks that we face in our business.

Jeffrey Walch
Bernstein Institutional Services LLC, Research Division

That’s perfect. And Michael, really appreciate you and the team coming out today. We’ve had you attend multiple of these conferences and really appreciate always hearing your story. And personally, I’m excited to have this conversation today. I worked with your company back when I was at Bristol-Myers Squibb. So I know Exelixis well as a drug collaborator.

Michael Morrissey
CEO, President & Director

That’s right, collaborator.

Jeffrey Walch
Bernstein Institutional Services LLC, Research Division

Yes, collaborators on dual LAG program. So look forward to a nice conversation and love to hear about your strategy and what you’re sort of thinking.